Athira Pharma FY2024 net loss $96.9M; cash burn continues; ATH-1105 Phase 1 complete; fosgonimeton paused

LeonaBio, Inc.

2024-FY EPS reported -$2.52

Cash, cash equivalents and investments $51.3M as of Dec 31, 2024, down from $147.4M; net cash used in operations $97.2M.
Net loss $96.9M ($2.52 per share) vs $117.7M ($3.09 per share) in 2023; R&D expenses $70.7M, G&A $26.1M.
Legal expense $4.1M accrued for settlement with DOJ related to NIH grant.
ATH-1105 Phase 1 in 80 healthy volunteers completed with favorable safety; on track to dose ALS patients in 2025.
LIFT-AD Phase 2/3 of fosgonimeton missed endpoints; development paused; exploring strategic alternatives with Cantor Fitzgerald.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.